Clinical Trial Update: A Trial of Alirocumab and Plaque Regression in Peripheral Arterial Disease [Phase 4]

View source ↗

Summary

Phase 4 trial update evaluating alirocumab for plaque regression in peripheral arterial disease has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Peripheral Arterial Disease

Drugs mentioned

• alirocumab (alirocumab)

Snippet

Sponsor: University of Virginia | Conditions: Peripheral Arterial Disease | Phase 4 | Status: COMPLETED